Discovering anti-platelet drug combinations with an integrated model of activator-inhibitor relationships, activator-activator synergies and inhibitor-inhibitor synergies

PLoS Computational Biology

Volumn 11, Issue 4, 2015, Pages

  Lombardi, Federica ^a,b   Golla, Kalyan ^b   Fitzpatrick, Darren J ^a   Casey, Fergal P ^a   Moran, Niamh ^b   Shields, Denis C ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

MERGERS AND ACQUISITIONS;

'CURRENT; COMBINATION EFFECTS; COMPLEX SIGNALLING; DRUG COMBINATIONS; INHIBITOR COMBINATION; INTEGRATED MODELING; ROBUST TESTS; SIGNALLING PATHWAYS; SYSTEM MODELS; THERAPEUTIC DRUGS;

PLATELETS;

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR; COLLAGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PURINERGIC P2Y12 RECEPTOR; THROMBIN RECEPTOR; THROMBOXANE RECEPTOR; WORTMANNIN; YOHIMBINE;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN EXPERIMENT; IC50; NORMAL HUMAN; PROTEIN SECRETION; PROTEIN TARGETING; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; CELL CULTURE; COMBINATION DRUG THERAPY; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG EFFECTS; PHYSIOLOGY; PROCEDURES; STATISTICAL MODEL; THROMBOCYTE;

BLOOD PLATELETS; CELLS, CULTURED; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG DISCOVERY; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MODELS, STATISTICAL; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS;

EID: 84929493559     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004119     Document Type: Article

References (44)

1. Moshfegh K, Redondo M, Julmy F, Wuillemin WA, Gebauer MU, Haeberli A, et al. (2000) Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. Journal of the American College of Cardiology 36: 699–705. 10987587
2. Al-Lazikani B, Banerji U, Workman P, (2012) Combinatorial drug therapy for cancer in the post-genomic era. Nature biotechnology 30: 679–692. doi: 10.1038/nbt.2284 22781697
3. Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, et al. (2007) Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer cell 11: 395–406. 17482130
4. Tang J, Karhinen L, Xu T, Szwajda A, Yadav B, Wennerberg K, et al. (2013) Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways. PLoS computational biology 9: e1003226. doi: 10.1371/journal.pcbi.1003226 24068907
5. Roemer T, Boone C, (2013) Systems-level antimicrobial drug and drug synergy discovery. Nature chemical biology 9: 222–231. doi: 10.1038/nchembio.1205 23508188
6. Lehar J, Stockwell BR, Giaever G, Nislow C, (2008) Combination chemical genetics. Nature chemical biology 4: 674–681. doi: 10.1038/nchembio.120 18936752
7. Lehar J, Zimmermann GR, Krueger AS, Molnar RA, Ledell JT, Heilbut AM, et al. (2007) Chemical combination effects predict connectivity in biological systems. Molecular systems biology 3: 80. 17332758
8. Takahashi K, Yamanaka S, (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663–676. 16904174
9. Haslam RJ, Dickinson NT, Jang EK, (1999) Cyclic nucleotides and phosphodiesterases in platelets. Thrombosis and haemostasis 82: 412–423. 10605732
10. Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM, et al. (1994) Cloning and expression of a cDNA for the human prostanoid IP receptor. The Journal of biological chemistry 269: 12173–12178. 7512962
11. Maurice DH, Haslam RJ, (1990) Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Molecular pharmacology 37: 671–681. 2160060
12. Offermanns S, (2006) Activation of platelet function through G protein-coupled receptors. Circulation research 99: 1293–1304. 17158345
13. Aktories K, Jakobs KH, (1984) Ni-mediated inhibition of human platelet adenylate cyclase by thrombin. European journal of biochemistry / FEBS 145: 333–338. 6437813
14. Offermanns S, Laugwitz KL, Spicher K, Schultz G, (1994) G proteins of the G12 family are activated via thromboxane A2 and thrombin receptors in human platelets. Proceedings of the National Academy of Sciences of the United States of America 91: 504–508. 8290554
15. Swift S, Sheridan PJ, Covic L, Kuliopulos A, (2000) PAR1 thrombin receptor-G protein interactions. Separation of binding and coupling determinants in the galpha subunit. The Journal of biological chemistry 275: 2627–2635. 10644723
16. McLaughlin JN, Shen L, Holinstat M, Brooks JD, Dibenedetto E, Hamm HE, (2005) Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. The Journal of biological chemistry 280: 25048–25059. 15878870
17. Djellas Y, Manganello JM, Antonakis K, Le Breton GC, (1999) Identification of Galpha13 as one of the G-proteins that couple to human platelet thromboxane A2 receptors. The Journal of biological chemistry 274: 14325–14330. 10318854
18. Knezevic I, Borg C, Le Breton GC, (1993) Identification of Gq as one of the G-proteins which copurify with human platelet thromboxane A2/prostaglandin H2 receptors. The Journal of biological chemistry 268: 26011–26017. 8245033
19. Newman KD, Williams LT, Bishopric NH, Lefkowitz RJ, (1978) Identification of alpha-adrenergic receptors in human platelets by [3H]dihydroergocryptine binding. The Journal of clinical investigation 61: 395–402. 23392
20. Yang J, Wu J, Jiang H, Mortensen R, Austin S, Manning DR, et al. (2002) Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. The Journal of biological chemistry 277: 46035–46042. 12297509
21. Cattaneo M, Canciani MT, Lecchi A, Kinlough-Rathbone RL, Packham MA, Mannucci PM, et al. (1990) Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood 75: 1081–1086. 2137716
22. Jin J, Daniel JL, Kunapuli SP, (1998) Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. The Journal of biological chemistry 273: 2030–2034. 9442040
23. Ezumi Y, Shindoh K, Tsuji M, Takayama H, (1998) Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets. The Journal of experimental medicine 188: 267–276. 9670039
24. Poole A, Gibbins JM, Turner M, van Vugt MJ, van de Winkel JG, Saito T, et al. (1997) The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. The EMBO journal 16: 2333–2341. 9171347
25. Watson SP, Asazuma N, Atkinson B, Berlanga O, Best D, Bobe R, et al. (2001) The role of ITAM- and ITIM-coupled receptors in platelet activation by collagen. Thrombosis and haemostasis 86: 276–288. 11487016
26. Gibbins JM, Briddon S, Shutes A, van Vugt MJ, van de Winkel JG, Saito T, et al. (1998) The p85 subunit of phosphatidylinositol 3-kinase associates with the Fc receptor gamma-chain and linker for activitor of T cells (LAT) in platelets stimulated by collagen and convulxin. The Journal of biological chemistry 273: 34437–34443. 9852111
27. Pasquet JM, Bobe R, Gross B, Gratacap MP, Tomlinson MG, Payrastre B, et al. (1999) A collagen-related peptide regulates phospholipase Cgamma2 via phosphatidylinositol 3-kinase in human platelets. The Biochemical journal 342 (Pt 1): 171–177.
28. Terstappen GC, Schlupen C, Raggiaschi R, Gaviraghi G, (2007) Target deconvolution strategies in drug discovery. Nature reviews 6: 891–903. 17917669
29. Chou TC, Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer research 70: 440–446. doi: 10.1158/0008-5472.CAN-09-1947 20068163
30. Greco WR, Bravo G, Parsons JC, (1995) The search for synergy: a critical review from a response surface perspective. Pharmacological reviews 47: 331–385. 7568331
31. Berenbaum MC, (1989) What is synergy? Pharmacological reviews 41: 93–141. 2692037
32. Chatterjee MS, Purvis JE, Brass LF, Diamond SL, (2010) Pairwise agonist scanning predicts cellular signaling responses to combinatorial stimuli. Nature biotechnology 28: 727–732. doi: 10.1038/nbt.1642 20562863
33. Lombardi F, De Chaumont C, Shields DC, Moran N, (2012) Platelet signalling networks: pathway perturbation demonstrates differential sensitivity of ADP secretion and fibrinogen binding. Platelets 23: 17–25. doi: 10.3109/09537104.2011.594190 22129436
34. StataCorp (2011) Stata statistical Software. Release 12. College Station, Texas: StataCorp LP.
35. Team RDC (2008) R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
36. Berlin I, Crespo-Laumonnier B, Cournot A, Landault C, Aubin F, Legrand JC, et al. (1991) The alpha 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. Clinical pharmacology and therapeutics 49: 362–369. 2015726
37. Yeh P, Tschumi AI, Kishony R, (2006) Functional classification of drugs by properties of their pairwise interactions. Nature genetics 38: 489–494. 16550172
38. Geva-Zatorsky N, Dekel E, Cohen AA, Danon T, Cohen L, Alon U, (2010) Protein dynamics in drug combinations: a linear superposition of individual-drug responses. Cell 140: 643–651. doi: 10.1016/j.cell.2010.02.011 20211134
39. Wood K, Nishida S, Sontag ED, Cluzel P, (2012) Mechanism-independent method for predicting response to multidrug combinations in bacteria. Proceedings of the National Academy of Sciences of the United States of America 109: 12254–12259. doi: 10.1073/pnas.1201281109 22773816
40. Dorsam RT, Kim S, Jin J, Kunapuli SP, (2002) Coordinated signaling through both G12/13 and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets. The Journal of biological chemistry 277: 47588–47595. 12297512
41. Chakraborty R, Bhullar RP, Dakshinamurti S, Hwa J, Chelikani P, (2014) Inverse Agonism of SQ 29,548 and Ramatroban on Thromboxane A2 Receptor. PloS one 9: e85937. doi: 10.1371/journal.pone.0085937 24465800
42. Li Z, Zhang G, Le Breton GC, Gao X, Malik AB, Du X, (2003) Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. The Journal of biological chemistry 278: 30725–30731. 12796499
43. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, et al. (2006) Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. European heart journal 27: 1166–1173. 16621870
44. Andre P, LaRocca T, Delaney SM, Lin PH, Vincent D, Sinha U, et al. (2003) Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis. Circulation 108: 2697–2703. 14597584